AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+36.42%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$615M
AUM Growth
+$615M
(+23%)
Cap. Flow
+$3.99M
Cap. Flow
% of AUM
0.65%
Top 10 Holdings %
Top 10 Hldgs %
41%
Holding
112
New
24
Increased
26
Reduced
15
Closed
21
Top Buys
| 1 |
Vera Therapeutics
VERA
|
$20.3M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$16.2M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$12.8M |
| 4 |
AUTL
Autolus Therapeutics
AUTL
|
$11.6M |
| 5 |
Kura Oncology
KURA
|
$11.5M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$41.6M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$25.8M |
| 3 |
Viking Therapeutics
VKTX
|
$20.5M |
| 4 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$19M |
| 5 |
LIAN
LianBio American Depositary Shares
LIAN
|
$16.9M |
Sector Composition
| 1 | Healthcare | 92.6% |
| 2 | Financials | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apogee Therapeutics
APGE
$2.17B
| $39.3M | 4.87% | 592,093 +55,000 | +10% | +$3.65M |
|
|
2
Xenon Pharmaceuticals
XENE
$2.98B
| $36M | 4.46% | 837,387 +377,387 | +82% | +$16.2M |
|
3
Madrigal Pharmaceuticals
MDGL
$9.76B
| $30.7M | 3.8% | 115,000 +15,000 | +15% | +$4.01M |
|
4
Crinetics Pharmaceuticals
CRNX
$2.92B
| $22M | 2.72% | 470,000 +22,905 | +5% | +$1.07M |
|
|
AUTL
5
Autolus Therapeutics
AUTL
$399M
| $21.5M | 2.67% | 3,375,000 +1,824,592 | +118% | +$11.6M |
|
6
Celldex Therapeutics
CLDX
$1.47B
| $21.4M | 2.65% | 510,000 +110,000 | +28% | +$4.62M |
|
7
Arcellx
ACLX
$3.85B
| $20.9M | 2.58% | 300,000 -40,000 | -12% | -$2.78M |
|
|
8
Vera Therapeutics
VERA
$1.38B
| $20.3M | 2.51% | +470,000 | New | +$20.3M |
|
|
INZY
9
DELISTED
Inozyme Pharma
INZY
| $20.2M | 2.51% | 2,642,519 +756,717 | +40% | +$5.8M |
|
10
Teva Pharmaceuticals
TEVA
$21.1B
| $19.8M | 2.45% | 1,400,000 -500,000 | -26% | -$7.06M |
|
|
11
Kura Oncology
KURA
$686M
| $15.6M | 1.93% | 730,492 +538,957 | +281% | +$11.5M |
|
12
Spyre Therapeutics
SYRE
$996M
| $15.6M | 1.93% | 410,000 -107,554 | -21% | -$4.08M |
|
|
VRNA
13
Verona Pharma
VRNA
$9.16B
| $13.2M | 1.63% | 817,833 +254,009 | +45% | +$4.09M |
|
|
ONC
14
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $12.8M | 1.59% | +82,143 | New | +$12.8M |
|
|
CERE
15
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $12.7M | 1.57% | 300,000 -450,000 | -60% | -$19M |
|
16
Nurix Therapeutics
NRIX
$714M
| $11.9M | 1.47% | 810,253 +120,141 | +17% | +$1.77M |
|
17
Astria Therapeutics
ATXS
$349M
| $11.9M | 1.47% | 845,606 -620,859 | -42% | -$8.74M |
|
18
Nuvalent
NUVL
$5.52B
| $11.3M | 1.39% | 150,000 -25,000 | -14% | -$1.88M |
|
19
Axsome Therapeutics
AXSM
$6.05B
| $11.2M | 1.38% | 139,758 +89,758 | +180% | +$7.16M |
|
20
Apellis Pharmaceuticals
APLS
$3.48B
| $9.7M | 1.2% | 165,000 +90,000 | +120% | +$5.29M |
|
|
CNTA
21
Centessa Pharmaceuticals
CNTA
$2.25B
| $9.39M | 1.16% | 830,546 +34,817 | +4% | +$393K |
|
22
Immunovant
IMVT
$2.56B
| $9.21M | 1.14% | 285,000 -60,000 | -17% | -$1.94M |
|
|
CMPS
23
Compass Pathways
CMPS
$424M
| $8.55M | 1.06% | 1,027,868 +477,868 | +87% | +$3.98M |
|
|
NARI
24
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $8.4M | 1.04% | 175,000 +155,000 | +775% | +$7.44M |
|
25
Establishment Labs
ESTA
$1.2B
| $8.38M | 1.04% | 164,589 -63,688 | -28% | -$3.24M |
|